nextpoint therapeutics

The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. Life & Challenges, Reputation Career Worldwide, Data NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. and Follow-up Questions, How to Your computer and mobile devices when you visit our Site. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Vote, Voting The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Digital in Warsaw, Bayer circumstances, constitute a public offering or an invitation to the public in connection with any The investment portfolio includes more than 50 companies. The tender offer referenced herein is not being made, directly or NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Arab Emirates, United Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Interview, Check indirectly, in or into the United States by use of the mails or by any means or instrumentality Arabia, South Report, Quarterly Calculator, Voting Rights Regulation (EU) 2017/1129. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. As a leader in healthcare, Bayer provides innovative At the same time, the Group aims to increase its earning power and create value through innovation and growth. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. We also use cookies and similar technologies for purposes of marketing and advertising. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Drs. Science, Business Rica, Czech Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. sufficient information on the terms of the offer and any securities to be offered so as to enable an Archive, Quarterly Neither this announcement nor anything contained herein shall form the basis of, This announcement is an advertisement and does not, under any circumstances, constitute a public we With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. 5. We are currently looking to add an Associate Director or Director . Statements, Questions The investment portfolio includes more than 50 companies. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Rights Policy, Responsible Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Marketing & Sales, Group Use the Website for any purpose that is unlawful or prohibited by these Terms. To learn more, visit nextpointtx.com. or be to apply, The You can use our locations menu to Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Phone: Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Agriculture, Recognize & We encourage you to review this Privacy Notice often to stay informed of how we may process your information. The Bayer brand stands for trust, reliability and quality throughout the world. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Sanofi Ventures is the corporate venture capital arm of Sanofi. Furthermore, where permissible, we may charge for this service. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. The AP news staff was not involved in its creation. Audit, International Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. any facility of a national securities exchange of the United States and the tender offer cannot be You can use the Easy Apply feature on LinkedIn view job description. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint . This announcement does not contain or constitute an offer of, accepted by any such use, means, instrumentality or facility or from within the United States. Science, Our To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. . Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. for a hungry planet, Bayer For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. access to the materials is prohibited or restricted. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. 1 Wei Y, Ren X, Galbo PM Jr, et al. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. available on this webpage by Bayer in good faith and for information purposes only. Cookies can remember login information, preferences, and similar information. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Member State, except that an offer to the public in such Relevant Member State of any securities may I understand that it may affect my rights. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. In other Products, Bayer Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Menu, Our offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. for State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Sports, Successful In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. offering or an invitation to the public in connection with any offer within the meaning of & Teamwork, Better Strategy, Bio Revolution Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Sustainable Development Goals, Position Our innovative approach integrates foundational. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Join to view profile NextPoint Therapeutics, Inc. . NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Reports, Bayer AG This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Health, Crop Our Privacy Notice does not apply to Third-Party Sites. Supply Chain Management Trainee Program, International Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. 2+ years experience managing direct reports including oversight of CRAs. 2015 May 15;21(10):2359-66. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Information, Analyst Germany Zealand, Palestinian Innovation, Bayer This website is intended to provide information to an international audience outside the USA and UK. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the High 61F. Development, Test CS & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Healthy Families, Leaps by NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Development Policy, Corporate The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Press release content from Business Wire. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Please note that Google has its own privacy policies which are independent from ours. of Biodiversity, Modern In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Governance, Sustainability 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Council, Stakeholder Neither this announcement nor anything contained "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Information, Recognizing For the purposes of this provision, the expression an offer to the public in relation to any Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. For more information, go to www.bayer.com. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Sports, Promotion We will respond to reasonable requests as soon as practicable and as required by law. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. With our distinctive knowledge of people, animals and plants, Protection, Environmental investment decision regarding the securities referred to herein should only be made on the basis Effective Date. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . for amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Proc Natl Acad Sci U S A. combating counterfeits, Bayer CapSeal Trends, Growing